A joint project of the European Group for Blood and Marrow Transplantation (EBMT) and the European Mantle Cell Lymphoma Network (EMCL) has produced a consensus report on the role of autologous and allogeneic HCT in MCL. Recommendations for use of autologous HCT include: auto HCT should be the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; and complete or partial remission should be achieved before autologous HCT. Recommendations in support of allogeneic HCT include: allogeneic HCT should be considered for patients relapsing after autologous HCT; reduced intensity conditioning regimens should be used; and allogeneic immunotherapy should be used for minimal residual disease eradication after allogeneic HCT.
Consensus Report: The Role of Autologous and Allogeneic HCT in MCL
Sep 2014